{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:09:40Z","timestamp":1787436580754,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Programa Operacional Factores de Competitividade \u2013 COMPETE"},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT), Portugal","award":["PEst-C\/SAU\/LA0001\/2013-2014"],"award-info":[{"award-number":["PEst-C\/SAU\/LA0001\/2013-2014"]}]}],"content-domain":{"domain":["lrjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.leukres.2014.12.008","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T00:46:27Z","timestamp":1419295587000},"page":"355-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Drug transporters play a key role in the complex process of Imatinib resistance in vitro"],"prefix":"10.1016","volume":"39","author":[{"given":"Raquel","family":"Alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Raquel","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Ferreira-Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Abrantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Rodrigues-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9nia","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Matoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel M.","family":"Carreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Filomena","family":"Botelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4142-4841","authenticated-orcid":false,"given":"Ana B.","family":"Sarmento-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2014.12.008_bib0005","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.leukres.2014.12.008_bib0010","first-page":"8","article-title":"Chronic myeloid leukaemia in the 21st century","volume":"76","author":"Frazer","year":"2007","journal-title":"Ulst Med J"},{"key":"10.1016\/j.leukres.2014.12.008_bib0015","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.12.008_bib0020","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.008_bib0025","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.008_bib0030","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"Hu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.12.008_bib0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2010.10.018","article-title":"Imatinib treatment in chronic myelogenous leukemia: what have we learned so far","volume":"300","author":"Breccia","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.leukres.2014.12.008_bib0040","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/07357907.2012.659925","article-title":"Apoptosis deregulation influences chemoresistance to azaguanine in human leukemic cell lines","volume":"30","author":"Sarmento-Ribeiro","year":"2012","journal-title":"Cancer Invest"},{"key":"10.1016\/j.leukres.2014.12.008_bib0045","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2014.12.008_bib0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-1759(97)00043-4","article-title":"Assessment of the Alamar Blue assay for cellular growth and viability in vitro","volume":"204","author":"Nakayama","year":"1997","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.leukres.2014.12.008_bib0055","series-title":"Current protocols in human genetics","author":"Dracopoli","year":"1994"},{"key":"10.1016\/j.leukres.2014.12.008_bib0060","series-title":"ISCN 2013: an international system for human cytogenetic nomenclature: recommendations of the international standing committee on human cytogenetic nomenclature","author":"Shaffer","year":"2012"},{"key":"10.1016\/j.leukres.2014.12.008_bib0065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0145-2126(00)00125-9","article-title":"Complete karyotype characterization of the K562 cell line by combined application of G-banding, multiplex-fluorescence in situ hybridization, fluorescence in situ hybridization, and comparative genomic hybridization","volume":"25","author":"Naumann","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.12.008_bib0070","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1182\/blood.V99.5.1874","article-title":"Comprehensive cytogenetic and molecular genetic characterization of the TI-1 acute myeloid leukemia cell line reveals cross-contamination with K-562 cell line","volume":"99","author":"Rush","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.008_bib0075","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 A Europe against cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2014.12.008_bib0080","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.leukres.2008.01.010","article-title":"High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain","volume":"32","author":"Pol\u00e1kov\u00e1","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2014.12.008_bib0085","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.nucmedbio.2009.11.001","article-title":"Hypoxia-induced redox alterations and their correlation with 99mTc-MIBI and 99mTc-HL-91 uptake in colon cancer cells","volume":"37","author":"Abrantes","year":"2010","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.leukres.2014.12.008_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","article-title":"Imatinib resistance in CML","volume":"274","author":"Volpe","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.leukres.2014.12.008_bib0095","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2014.12.008_bib0100","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.008_bib0105","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","article-title":"The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia","volume":"121","author":"Giannoudis","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.008_bib0110","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2014.12.008_bib0115","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.008_bib0120","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.008_bib0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","article-title":"ABCG2: a perspective","volume":"61","author":"Robey","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.leukres.2014.12.008_bib0130","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1021\/mp100040f","article-title":"A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib","volume":"7","author":"Graber-Maier","year":"2010","journal-title":"Mol Pharm"},{"key":"10.1016\/j.leukres.2014.12.008_bib0135","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.4161\/cc.3.12.1331","article-title":"Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib","volume":"3","author":"Burger","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.leukres.2014.12.008_bib0140","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2014.12.008_bib0145","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4236\/jct.2011.23056","article-title":"Efflux pumps modulation in colorectal adenocarcinoma cell lines: the role of nuclear medicine","volume":"2","author":"Casalta-Lopes","year":"2011","journal-title":"J Cancer Ther"},{"key":"10.1016\/j.leukres.2014.12.008_bib0150","first-page":"5010","article-title":"Drug transporters in imatinib resistance: a new therapeutic targeted approach In CML","volume":"118","author":"Alves","year":"2011","journal-title":"ASH Annu Meet Abstr"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614003919?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212614003919?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T15:54:59Z","timestamp":1537977299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614003919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0145212614003919"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2014.12.008","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug transporters play a key role in the complex process of Imatinib resistance in vitro","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2014.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}